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Abstract
Background: Hypo-fractionated stereotactic radiotherapy (HSRT) is emerging as a valid treatment option for
patients with single, large brain metastases (BMs). We analyzed a set of our patients treated with HSRT. The aim
of this study was to evaluate local control (LC), brain distant progression (BDP), toxicity and overall survival (OS).
Methods: From July 2011 to May 2015, 102 patients underwent HSRT consisting of 27Gy/3fractions for lesions
2.1–3 cm and 32Gy/4 fractions for lesions 3.1–5 cm. Local progression was defined as increase of the enhancing
abnormality on MRI, and distant progression as new brain metastases outside the irradiated volume. Toxicity in
terms of radio-necrosis was assessed using contrast enhanced T1MRI, T2 weighted-MRI and perfusion- MRI.
Result: The median maximum diameter of BM was 2.9 cm (range 2.1–5 cm), the median gross target volume (GTV)
was 16.3 cm3 and the median planning target volume (PTV) was 33.7 cm3 The median,1,2-year local control rate
was 30 months, 96, 96 %; the median, 1–2-year rate of BDP was 24 months, 12, 24 %; the median,1,2-year OS was
14 months, 69, 33 %. KPS and controlled extracranial disease were associated with significant survival benefit
(p <0.01). Brain radio-necrosis occurred in six patients (5.8 %).
Conclusion: In patients with single, large BMs unsuitable for surgical resection, HSRT is a safe and feasible
treatment, with good brain local control and limited toxicity.
Keywords: HSRT, Volumetric modulated arc therapy, RapidArc, Brain metastases
Background
Brain metastases (BMs) occur in 20–40 % of adult cancer
patients and the incidence increased two to five times over
the last 40 years [1, 2]. In cases of single, large BMs, the
treatment approach includes surgical resection, whole
brain radiation therapy (WBRT) and stereotactic radiosur-
gery (SRS). Although surgical resection is the main treat-
ment option, many patients are unsuitable for surgery due
to their general condition, Karnofsky Performance Scale
(KPS), age and comorbidity, critical location of lesions or
uncontrolled primary tumor and/or extracranial meta-
static site. For several years, WBRT has been considered
the standard of care for these cancer patients but consid-
ering the poor local control (LC) rate in the case of large
brain lesions [3], other radiation therapy modalities were
investigated. SRS, whether combined or not with WBRT,
is increasingly used for patients with solitary or limited
BMs (up to four) with a recorded local control of 70–90 %
at 12 months [4–7]. However, SRS, using the dose guide-
lines recommended by the Radiation Therapy Oncology
Group (RTOG) 90-05 study, achieves a LC of 49 % in me-
tastases between 2.1 and 3 cm and of 45 % in metastases
between 3.1 and 4.0 cm [7]. On this topic, literature data
showed a 3-fold increased risk of local failure for tumor
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treated with 15–18Gy compared to 24Gy, with a 1-year
local control <50 % [8]. On the other hand, single large
doses may be associated with an increased risk of neuro-
logic morbidity from radiation necrosis, and this is of con-
cern especially for lesions larger than 2.5–3.0 cm or that
are in close proximity to critical structures, such as optic
apparatus or brainstem [8–13]. In such cases, hypo-
fractionated stereotactic radiotherapy (HSRT) using up to
five fractions was employed with the aim to maintain a
high local control rate whilst decreasing the late radiation-
induced toxicity. There is limited evidence for the treat-
ment of larger brain metastases, specifically those greater
than 3 cm in maximum diameter. Many of published
studies, included patients treated both for small and for
large lesions and results were not stratified according to
the tumor size [14–25]. In our department, we choose to
treat patients with single large (≥2.1 cm) BMs, unsuitable
for surgical resection, using a multi-fraction stereotactic
radiotherapy rather than SRS in a single session. This ana-
lysis concerns only patients with single large BMs treated
in this way. Primary objective was to evaluate the safety
and the feasibility of HSRT in terms of toxicity and its im-
pact on brain LC. In addition, brain distant progression
(BDP) and overall survival (OS) were evaluated.
Methods and materials
Patients and procedures
The present retrospective study includes patients with
single large BMs. All patients were treated in agreement
with the Helsinki declaration. This study was based on a
retrospective analysis of treatment charts and received
approval by the Humanitas Hospital Ethical Committee.
All patients, during admission, signed a consent to the use
of their data for scientific scopes. To define the appropri-
ate therapy, each patient was evaluated by a multidiscip-
linary team including a neurosurgeon, a neuro-oncologist
and a radiation oncologist. HSRT was performed when at
least one of the following conditions was met: 1) KPS ≥70,
2) oligo-metastatic disease, defined as the presence of up
to a total of five metastatic lesions, both cranial and extra-
cranial, 3) histological diagnosis of primary solid tumor
excluding small cell lung cancer (SCLC) and lympho-
proliferative disease, 4) single, large BMs (≥2.1 cm), 5)
contra-indication to surgical resection for patients general
condition, uncontrolled extra-cranial metastases, and crit-
ical location of BMs. Patients with lesions ≤2 cm were ex-
cluded from this analysis, as they undergo single dose
stereotactic radiosurgery (SRS). To precisely delineate the
target volume, enhanced T1-MRI sequences and post-
contrast CT scans were acquired and co-registered. Pa-
tients were placed in supine position with arms close to
the body. A personalized thermoplastic mask was used for
patient immobilization and repositioning. All CT scans ex-
tending from the top of the skull to the third cervical
vertebrae were acquired with 1 mm slice thickness and
imported in the iPlan-net Brainlab stereotactic treatment
planning system (Brainlab Ag, Feldkirchen, Germany). An
automatic rigid co-registration was performed for all pa-
tients. Gross tumor volume (GTV) consisted of the abnor-
mality on enhanced contrast T1-MRI; clinical target
volume (CTV) corresponded to GTV and no additional
margins were used; planning target volume (PTV) was
generated adding an isotropic margin of 3 mm from CTV.
This was chosen as a safety upper limit due to the use of
relocable thermoplastic masks rather than fixed localizers.
Organs at risk (OARs) delineated were brain, brainstem,
optic nerves, chiasm and lenses. No margins were added
to OARs. All plans were optimized on PTV. The pre-
scribed total dose and fractionation was chosen in relation
to the size of BMs and/or to the close proximity of OARs:
for lesions between 2.1 and 3 cm the schedule used was
27Gy in three daily fractions, and for lesions between 3.1
and 5 cm or located near to optic apparatus or brain stem
was 32Gy in four daily fractions. The objective was to ob-
tain a biological equivalent dose (BED) for tumor (BED10)
>50Gy. As per the institutional policy in these patients,
the planning objective for OARs was to minimize as much
as possible the dose to normal brain tissue. The upper
dose-volume constraints used for brainstem, optic appar-
atus, and lenses were D1% ≤20Gy, D1% ≤15Gy, and D1%
<1Gy, respectively. The constraint for the mean dose to
the brain was 4Gy (i.e. to the entire healthy brain without
volume thresholds). No other specific dose-volume con-
straints were applied to other structures. Plans were opti-
mized aiming to achieve a PTV coverage of D95% >95 %
with a homogeneous dose distribution. The AAPM task
group 101 suggests prescribing SBRT or SRS at a specific
isodose (usually approximately 80 %). However, the mod-
ern algorithms of inverse TPS intrinsically intend to obtain
homogeneous dose to the PTV, because the systems were
primarily designed for conventional fractionated RT treat-
ment. Moreover, ICRU 83 suggests normalizing to a mean
value without specifically distinguishing between the stand-
ard RT and stereotactic treatments [26]. Normalization was
set in order to have 100 % of the dose to target (PTV)
mean. All plans were optimized using two partial co-planar
or non co-planar arcs, according to the lesion position as
shown in Fig. 1. All patients were treated with the volumet-
ric modulated arc technique RapidArc (Varian Medical
System, Palo Alto, USA) on three different Varian Linacs
equipped with a 4D couch. Exactrac (Brainlab) and Cone
Beam CT imaging was performed daily for patient set up
and positioning verification.
Outcome evaluation
Clinical outcome was evaluated by neurological examin-
ation and a brain MRI was performed two months after
RT and then every 3 months. Local progression was
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defined as radiographic increase of the enhancing abnor-
mality in the irradiated volume on serial MR imaging.
Distant failure, instead, was defined as the presence of
new brain metastases or leptomeningeal enhancement
outside the irradiated volume. LC was assessed and re-
ported for alive patients while the OS analysis was per-
formed on all patients. Toxicities were graded according
to Common Terminology Criteria for Adverse Events
version 4.0. Radio-necrosis was assessed using contrast
enhanced T1MRI, T2 weighted-MRI and perfusion-MRI.
Radio-necrosis was considered as the presence of central
hypo-density and peripheral enhancement on T1-weighted
post-contrast imaging, with edema on T2-weighted se-
quences and a clear lack of perfusion without any nodular
highly vascularized area within the contrast enhanced
lesion on perfusion MRI. Histologic confirmation of
radio-necrosis was not required except for patients in
which surgical resection has been needed. Patients with
uncontrolled extracranial disease, at the first examination
time, underwent systemic therapy, chemotherapy, hormo-
nal therapy or biological target therapy, as appropriate for
the tumour histology.
Statistical analysis
Standard descriptive statistics (mean, standard deviation
and cross tabulation analysis) were used to describe the
general data behavior. Survival and recurrence time obser-
vations were plotted according to the method of Kaplan
and Meier, starting from the date of HSRT. The log-rank
test was used to carry out the univariate analysis, in order
to investigate the prognostic role of individual variables.
For analysis, variables analyzed were age, KPS, histology of
primary tumor, extracranial disease status (controlled/un-
controlled) at the time of HSRT, recursive partitioning
analysis (RPA) class, diagnosis- specific Graded Prognostic
Assessment (DS-GPA), and size of BMs. Groups were de-
fined according to discrete volume of each variables. For
age the analysis was dichotomized according to 65 years
threshold. Multivariate Cox model was used as a method
to estimate the independent association of a variable set
with overall survival (OS), local control (LC), and brain




From July 2011 to May 2015, among patients referred to
our institution for BM, 102 patients with single, large
BMs eventually underwent HSRT. Of these patients, 39
(38 %) were female and 63 (62 %) male, with a median
age of 61 years (range 30–93 years). The most common
primary cancers were lung, breast, and melanoma. BMs
were present at diagnosis in 51 patients (50 %), whereas
they developed in 51 (50 %) after primary tumor treat-
ment. At the time of BMs diagnosis, 66 (65 %) had also
additional extracranial metastatic localizations. No pa-
tients had uncontrolled primary tumor. Based on RPA
class which considers age, KPS, controlled primary tumor
and extracranial metastases [27], 18 (18 %) patients were
in RPA class I, 81 (79 %) in RPA class II and 3 (3 %) in
Fig. 1 Treatment plan of patient with left cerebellum metastases by Volumetric modulated arc therapy (VMAT) using two partial co-planar arcs
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RPA class III. In relation to GPA score [28] which con-
siders histology of primary tumor, age, KPS, presence of
extracranial metastases and number of cranial metastases,
12 (12 %) patients had a GPA score between 0 and 1.0, 54
(53 %) a GPA score between 1.5 and 2.5, 21 (20 %) a GPA
score three, and 15 (15 %) a GPA score between 3.5 and 4.
Details about tumor specific GPA are shown in Table 1.
Fifty-one (50 %) lesions received 27Gy, 9Gy per fraction in
three consecutive days and 51 (50 %) lesions received
32Gy, 8Gy per fraction in four consecutive days. Patient’s
tumor and treatment characteristics are shown in Table 1.
The median maximum diameter of BMs was 2.9 cm
(range 2.1–5 cm), the median GTV was 16.3 cm3 (range
3.9–64.5 cm3) and the median PTV was 33.7 cm3 (range
9.2–22.3 cm3). Details about GTV and PTV are shown in
Table 2. For all patients the required dose objectives for
Table 1 Patients, tumor and treatment characteristics




Age (median) 61 years (range 30–93 years)
Histology
Breast Cancer 18 17
NSCLC 57 56
Melanoma 12 12
Other (CCC, Colon) 15 15
Stage at diagnosis of primary tumor
I–III 51 50
IV 51 50









GPA score 0–1 1.5–2.5 3 3.5–4
Breast cancer 0 6 12 0
NSCLC 12 36 3 6
Melanoma 0 0 6 6
Other 0 12 3 0
Other extracranial metastatic site at diagnosis of BM 66 65
BM median maximum diameter cm (range cm) 2.9 (2.1–5)
BM diameter cm
2.1–3 cm 51 50
3.1–5 cm 51 50
GTV median volume cm3 (range cm3) 16.3 (3.9–64.5)
PTV median volume cm3 (range cm3) 33.7 (9.2–122.3)
HSRS Total dose/dose per fraction/n fractions
27 Gy/9 Gy/3 51 50
32 Gy/8 Gy/4 51 50
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target coverage, organs at risk and for healthy brain were
respected and, concerning mean dose to the healthy brain,
for the majority of the plans the mean dose was much
lower than 4Gy.
Clinical outcomes
With a median follow-up of 14 months (range 3–53
months), local progression at the site of HSRT occurred
in 6 (5.8 %) patients at a mean time of 22 months (range
9–35 months); the total dose delivered was 27 Gy in three
fractions in three patients and 32 Gy in four fractions in
the others three. For the entire cohort, the median, 1 and
2-year local control rate of alive patients was 30 months,
96 and 96 %, respectively (Fig. 2a). Thirty (29 %) patients
had new brain metastases at distant brain sites, and in 12
(40 %) patients progressive extracranial disease was
present too. The median, 1 and 2-year rate of developing
new brain metastases was 24 months (range 3–53
months), 12 and 24 %, respectively as shown in Fig. 2b.
On univariate and multivariate analysis neither gender,
age, KPS, histology of primary tumor, extracranial disease
status (controlled/uncontrolled) at the time of HSRT, re-
cursive partitioning analysis (RPA) class, diagnosis-specific
Graded Prognostic Assessment (DS-GPA), nor size of
BMs were predictive of LC or BDP. The median, 1 and 2-
year OS was 14 months, 69, 33 %, respectively as shown
in Fig. 2c. In relation to RPA class the median, 1 and 2-
year OS was 18 months, 66.6 and 33.3 % for patients in
RPA class I, 15 months, 72 and 36 % for RPA class II and
9 months, 37.5 and 0 % for RPA class III. Considering
GPA, patients with score 3.5–4 had a better outcome
compared with score 0–1 with a median OS of 14 months
(range 3–14 months) vs 9 months (range 6–10 months)
without statistical relevance (p = 0.07). The results for the
analysis stratified according to the dose fractionation
schedule are shown in Fig. 3. The median, 1 and 2 years
LC rate for alive patients were 30 months, 100 and 100 %
for 27 Gy/3 fractions vs (median not reached), 91 and
91 % for 32 Gy/4frs (p = 0.25); the median, 1 and 2 years
BDP rate were (median not reached), 10 and 10 % for
27 Gy/3 fractions vs 26 months, 14.3 and 35.7 % (p = 0.23);
the median, 1 and 2 years OS were 14 months, 60 and
27.4 % for 27 Gy/3 fractions vs 14 months, 80 and 37 %
(p = 0.84). At the last observation time 45 (44 %) patients
were alive and 57 (56 %) dead. Among dead patients 42
(73.7 %) died for progressive extracranial disease at a me-
dian time of 14 months (range 8–31 months), and in 15
(26 %) of these also brain progression occurred; 9 (15.8 %)
patients died for intracranial progression at a mean time
of 12 months (range 9–17 months) and 6 (10.5 %) of cere-
bral bleeding within 5 months from HSRT. No relations
were recorded for the events in relation to the total dose
delivered, and fractionation used. In fact, among nine pa-
tients died for intracranial progression, four received
27 Gy in three fractions and five patients were treated
with 32 Gy in four fractions; similarly for cerebral blend-
ing, three patients received 27 Gy and three received
32 Gy. On univariate and multivariate analysis KPS and
controlled extracranial disease were associated with the
better prognosis (p <0.01).
Toxicity
Steroid dependency occurred in 12 patients who re-
ceived high-dose dexamethasone for more than 6 months
in relation to the increased perilesional edema. No close
correlation was recorded in respect to the RT scheme
used, as half of these have received 27 Gy in three frac-
tions and the other 32 Gy in four fractions. Among
these, six patients had progressive symptoms uncon-
trolled by medical drugs and in such patients surgical re-
section was required for grade 3 radio-necrosis. No
severe grade IV toxicities occurred. Minor disorders
were represented by grade I-II headache in 12 patients,
grade I-II hydrocephalus in six, and grade I-II ischemia
cerebrovascular in six. No visual or new motor sensory
deficits were recorded for patients treated for lesions in
close proximity of optical nerves, chiasmas or brainstem.
Six (5.8 %) cases of brain radio-necrosis occurred,
and surgical resection was performed. Histological data
confirmed the presence of extensive radio-necrosis that
occurred at a mean time of 11 months (range 10–12
months) from HSRT. Considering the few cases observed,
it was not possible to evaluate the relation between dose
level and volume. In these patients the BMs were larger
than 4.1 cm in maximum diameter, the PTV was between
72.4 and 122.3 cm3 and the total dose given was 32 Gy/4
fractions.
Table 2 Gross target volume (GTV) and planning target volume
(PTV) of the entire cohort of patients treated for single large
brain metastases (BMs)
Median GTV and range for the entire cohort 16.3 cm3(3.9–64.5 cm3)
GTV cm3 (range cm3) n. patients %
≤4 (3.9–4) 9 8.8
4.1–10 (4.36–9.76) 27 26.5
10.1–20 (10.88–19.81) 30 29.4
21–40 (22.63–39.37) 21 20.6
>40 (42.61–64.5) 15 14.7
Median PTV and range for the entire cohort 33.7 cm3(9.2–122.3 cm3)
PTV cm3 (range cm3) n. patients %
<10 (9.2–10) 9 8.8
>10–24 (10.1–23.1) 27 26.5
>20–38 (21.2–36.7) 30 29.4
40–85 (40–72.37) 21 20.6
>85 (88.6–122.3) 15 14.7












































































Fig. 2 Actuarial curves for the entire cohort of patients. a Local control (LC) of patients treated with hypo-fractionated stereotactic radiotherapy















































































Fig. 3 Analysis stratified according to the two dose fractionation schedules. a Local control (LC) of patients treated with hypo-fractionated
stereotactic radiotherapy (HSRT); b Brain distant progression (BDP); c Overall Survival (OS)
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Salvage treatment for intracranial/local progression
Among 36 brain relapse patients, six had local progres-
sion in site of HSRT and 30 in other brain site. The six
patients with local progression had also diffuse extracra-
nial progression and died early. About 30 patients with
BDP, 21 received single section stereotactic radiosurgery
(SRS) to other brain site and nine did not undergo fur-
ther treatment for widespread disease progression. No
patients had WBRT. Among the re-treated patients, 12
were alive at 6 months and nine patients dead within
7 months.
Discussion
The treatment of patients with single, large brain metas-
tases, unsuitable for surgical resection, is a challenge.
Several radiation strategies have been used and described
in literature: whole brain radiation therapy (WBRT), sin-
gle dose stereotactic radiosurgery (SRS) and more re-
cently multi-fraction or hypo-fractionated stereotactic
radiotherapy (HSRT). WBRT has been the mainstay of
treatment, but local control of single, large brain metas-
tases is suboptimal [3, 4]. Nieder analyzed the efficacy of
WBRT in 108 patients treated for 336 BMs. The LC rate
was 52 % for metastases <0.5 cm3 and 0 % for those
>10 cm3. Authors concluded that considering the low
LC using WBRT to a total dose of 30Gy even for small
metastases, patients should be treated with locally more
effective dose and fractionation schedules when local
control is the aim [3]. As well as achieve an inadequate
LC, WBRT has several drawbacks: takes more time to
deliver (2–3 weeks), thereby delaying systemic therapy
that in metastatic disease is fundamental; results in loss
of hair which can impact on patients’ quality of life; re-
quires the use of steroid for a longer time, generating in
some cases, many different comorbidities. In addition,
the neurocognitive effects of WBRT are becoming in-
creasingly important as improved systemic therapies in-
crease life expectancy for patients with brain metastases.
The RTOG 9508 randomized trial [4] evaluated patients
with one to three newly diagnosed brain metastases re-
ceiving SRS with WBRT or SRS alone showed a decline in
learning and memory function for patients who under-
went WBRT compared to SRS alone (54 % vs 24 %). Al-
though, these data revised using a different neurocognitive
test showed a minor decline in neurocognitive function,
this report increased the interest in omitting WBRT when
possible [29]. Another RT strategy is represented by SRS,
whether combined or not with WBRT that it is becoming
the major treatment used for patients with solitary or
limited BM (up to four). The RTOG protocol 90-05,
suggested three dose levesl based on maximal tumor
diameter [7], 24 Gy for lesions with maximal diameter
≤20 mm, 18 Gy in case of lesions 21–30 mm, and 15 Gy
for 31–40 mm in maximum diameter. As reported by
Vogelbaum a dose of 24 Gy to the tumor margin had a
significantly lower risk of local failure than 15 or 18 Gy
(p =0.0005; hazard ratio 0.277, confidence interval [CI]
0.134–0.573). With a 1-year local control rate of 85 %
(95 % CI 78–92 %) compared with 49 % (CI 30–68 %)
for tumors treated with 18 Gy and 45 % (CI 23–67 %)
for tumors treated with 15 Gy. [8]. Chang [30] identified a
1-cm cutoff for radiosurgical control of BMs; instead using
20 Gy or more in single fraction radiosurgery, the 1- and
2-year actuarial local control rates for lesions of 1 cm
(0.5 cm3) or less were 86 and 78 %, respectively, compared
to 56 and 24 %, for lesions larger than 1 cm (0.5 cm3)
(p <0.001). Other reports, defined a total tumor volume
cutoff value of ≥2 cm3 (p = 0.008) as a stronger predictor
of overall survival, distant brain failure and local control
rate (p <0.001) [10–12]. Although, comparative studies
of SRS and multi-fractions radiosurgery are not available,
the published data confirmed that for large BMs,
using a single dose radiosurgery, local control has proven
to be inadequate.
These unsatisfying outcomes make HSRT a valid alter-
native for large brain metastases. Generally, the advan-
tages of HSRT seem to be the following: i) the possibility
to treat large brain lesions (≥2.1 cm) with lower risk of
important radiation-induced neurotoxicity compared to
single dose SRS; ii) the feasibility to treat lesions near to
critical structures using few fractions of radiotherapy; iii)
a theoretical advantage due to the re-oxygenation of
hypoxic tumor cells between fractions; iv) an inferior
risk of brain radio-necrosis compared to SRS; v) keeping
a short treatment time compared to WBRT. In the re-
cent years, several published papers about this issue, re-
ported encouraging results with a 1-year LC ranging
from 56 to 93 %, a median OS between 8 and 16 months
and a 1-year rate of 34–66 %, and severe toxicity be-
tween 2 and 10 % as shown in table 3 [14–25]. Unfortu-
nately, these series are extremely heterogeneous for total
dose and schedules used, number of fractions, different
methodology utilized, different results recorded, more
than 1 BMs treated at the same time, inclusion of small
and large lesions without results divided in relation to
volume of BMs, and to date a suggestion on the optimal
treatment is not provided. Our series includes only
patients with single, large (≥2.1 cm) BM unsuitable
for surgical resection, underwent HSRT. Two different
schedules were used in relation to the tumor size,
27Gy in three consecutive daily fractions or 32Gy in
four consecutive daily fractions. The optimal fractionation
schedule for HSRT, has not yet been established. Different
total doses and schedules have been used with the aim to
keep a biological equivalent dose (BED) of about 60Gy10
(BED in Gy with α/β = 10) for tumor effects and BED of
about 150Gy3 (BED in Gy with α/β = 3) for late effects.
We chose to treat patients with a total dose corresponding
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to a BED10 greater than 50Gy considering the large vol-
ume treated. Using this approach, a local control rate of
96 % at 2 years was obtained. No differences were re-
corded in relation to the size of BM, 2.1–3 cm or 3.1–
5 cm. Survival rates were also encouraging, with a median,
1 and 2-year OS of 14 months, 69 % and 33 %, respect-
ively. Similar results were showed in the study of Minniti
[23]. Two different schedules of HSRS for 171 BMs
treated were used in relation to the tumor size. Patients
with tumor <2 cm received 36Gy in three fractions while
patients with tumor ≥2 cm were treated with 27Gy in
three fractions. The 1-year LC was 88 % and it was similar
in both groups, and the median and 1 year OS was
14.8 months and 57 % respectively. The limitation of this
study was that small brain lesions, potentially suitable for
SRS, were included in this analysis. The study of Fahrig is
one of the largest studies about this issue [16] evaluating
the outcome of 150 patients treated for 228 BM; different
doses and schedules were used in relation to the size and
location of the lesions. The 1-year LC was 93 % and the
median and 1 year OS was 16 months and 66 % respect-
ively but for BMs larger than 15 cm3 (maximum diameter
>3 cm) a longer schedule of HSRT (10 fractions) was also
used. The other published studies are limited for number
of patients enrolled, and/or for median local control and
survival not reported, and/or for inclusion of patients
underwent surgical resection too [14, 15, 17, 19, 20, 24, 25].
Concerning toxicity, in different series, no severe grade III-
IV neurological deficit were showed and symptomatic
radio-necrosis occurred in less than 10 % of patients. Limits
are that different methods were utilized for defining
radio-necrosis and few studies showed data about this
matter. Minniti showed that radio-necrosis occurred
in nine patients (9 %), leading to severe neurologic
complications in 5 (5 %) of them. The V24Gy was the most
significant predictor of radio-necrosis, with a cumulative
risk of 14 % for volumes >16.8 cm3 and 4 % for volumes
≤16.8 cm3 [23]. Ernst-Stecken showed that side effects,
i.e., increase in T2w-signal area, duration of steroid intake
and size of new or progressive necrotic centre of metasta-
sis, were dependent on the volume of normal brain irradi-
ated with more than 4Gy per fraction (V4Gy) [15]. Kim,
evaluating efficacy and toxicity of SRS compared to HSRT
in 98 patients with BMs, showed similar LC and OS rates
with a lower risk of toxicity for HSRT patients in compari-
son to those treated with SRS, despite the fact that HSRT
was used for large lesions and lesions in adverse locations
(17 % vs. 5 %, p = 0.05) [19]. In our series, no severe grade
III–IV disorders were recorded and no visual or new
motor-sensory deficit were observed for patients treated
for lesions in close proximity of optical nerves, chiasmas
or brainstem. Symptomatic radio-necrosis occurred in a
limited number of patients (5.8 %) considering the large
volume treated (91 % of lesions greater than 10 cm3), and
they were patients with lesions larger than 4.1 cm in max-
imum diameter and volume greater than 70 cm3 suggest-
ing that in these lesions a dose reduction should be
considered. We are aware that our analyses has the limit
of a retrospective study including patients with different
histological subtypes, above all in RPA class II and in
which GPA score was not represented in the entire cohort
of patients. However, HSRT for patients with large brain
metastases unsuitable for surgical resection has proven to
be a safe and effective treatment with a high rate of local
control and negligible toxicity. The use of new advanced
RT techniques as volumetric modulated arc therapy per-
mitted a high conformity for the tumor with maximum
sparing of normal structures. This can be considered the
Table 3 Some of larger published papers about hypo-fractionated stereotactic radiotherapy (HSRT) alone for large brain metastases
Authors N. pts Total dose/n.frs mLC mos 1 yr b LC% mOS mos 1 yr b OS% Toxicity %
Aoyama [14] 87 35 Gy/4 NR 81 8.7 39 5
Ernst-Stecken [15] 51 35 Gy/5 7 76 % 11 NR 2
Fahrig [16] 150 30–35 Gy/5 NR NR 16 66 10
40 Gy/10 0
35 Gy/7
Narayana [17] 20 30 Gy/5 NR 70 8.5 64.5 2
Kim [19] 40 36 Gy/6 NR 69 8 34 5
Ogura [20] 39 35 Gy/5 NR 86.7 64.5 2
Minniti [23] 135 36 Gy/3 NR 88 14.8 57 7
27 Gy/3
Rajakesari [24] 70 25 Gy/5 17 56 10.7 NR 4.3
Croker [25]a 61 24 Gy/3 9 69 21 60 7
Pts patients, frs fractions, mLC median local control, yr year, mOS median overall survival, mos months
aIncluding patients underwent surgery plus hypofractionated stereotactic radiosurgery (HSRS)
bActuarial
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main reason of the good treatment tolerance, and the
lower incidence of radio-necrosis. The low toxicity re-
corded allowed, in case of brain distant progression, to
perform a new outpatient radio-surgical treatment. More
than 50 % of patients retreated are alive at about 6 months.
One may argue that in our series, no WBRT was per-
formed. Our choice, however, has proved to be winning,
in fact only 12 and 24 % of patients had a BDP at 1 and
2 years, respectively. Finally, the observed OS was princi-
pally correlated with patients KPS, and controlled extra-
cranial disease. The control of large brain metastases,
however, in addition to improving quality of life, might
affect survival in a selected group of patients with good
KPS, controlled extracranial disease, and limited BMs.
Conclusion
In conclusion, in patients with single, large BM unsuitable
for surgical resection, HSRT is a safe and feasible treat-
ment, with good brain local control and limited toxicity.
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